Yahoo Finance

• FX Neutral EBITDA Growth: 20% growth target for 2024 achieved.

• Q4 FX Neutral Adjusted Growth: 28% with margin expanding 3.1 percentage points year-over-year.

• Revenue: Grew 11% on an FX neutral basis to approximately PEN1.1 billion in Q4; full year revenue nearly PEN4.4 billion, up 12% from 2023.

• Capacity Utilization: Increased 2.6 percentage points to 66%.

• Plan Memberships in Peru: Increased 7.4% for health plans; oncology memberships up 1.6%.

• Oncology MLR: Decreased 0.7 percentage points to 53%.

• Debt Leverage: Reduced to 3.6 times at year-end.

• Net Income: PEN124 million for the year, a PEN338 million improvement from a PEN214 million net loss in 2023.

• Mexico Revenue Growth: 9% increase in Q4; adjusted EBITDA up 30% in local currency.

• Peru Revenue Growth: 10% increase in Q4; adjusted EBITDA up 33% for the quarter and 51% for the year.

• Colombia Revenue Growth: 14% increase in local currency in Q4; adjusted EBITDA up 23% in local currency.

• Adjusted Net Income: PEN36 million in Q4, up from PEN6 million in Q4 2023.

• Cash Position: Improved to PEN236 million at year-end, an 18% sequential increase.

• Free Cash Flow: PEN432 million generated in 2024; organic free cash flow PEN509 million, up 18% from 2023.

• Interest Paid: PEN503 million, down 19% from 2023.

• Warning! GuruFocus has detected 4 Warning Signs with AUNA.

Release Date: March 11, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Auna SA (NYSE:AUNA) achieved a 20% FX neutral EBITDA growth target for 2024, demonstrating strong financial performance.

• The company reported a 28% FX neutral adjusted growth in the fourth quarter, with margin expansion of 3.1 percentage points versus last year's quarter.

• Auna SA (NYSE:AUNA) successfully signed a five-year exclusivity agreement with leading oncologists in Monterrey, positioning itself as a key oncology player in the region.

• The company's debt leverage fell to 3.6 times at year-end, indicating improved financial stability.

• Auna SA (NYSE:AUNA) reported a net income of PEN124 million for the year, a significant improvement from a net loss of PEN214 million in 2023.

Negative Points

• Challenges remain in Colombia, with additional provisions impacting financial results and a cautious approach being taken to limit risk exposure.

• The healthcare system in Colombia is under stress, affecting Auna SA (NYSE:AUNA)'s operations and requiring a conservative approach to growth.

• Seasonality effects in Mexico and Peru lead to variations in surgical volumes, impacting quarterly performance.

• The company faces uncertainty in Colombia due to government interventions and payer issues, affecting revenue predictability.

• Auna SA (NYSE:AUNA) is not providing specific guidance for 2025 due to uncertainties in the Colombian market, impacting investor confidence.